Kaplan Fox is Investigating Medline Inc. (MDLN) for Investors Who Suffered Losses
Newsfile Corp•06/10/2026•16:50 ET
0
Key Highlights
- ➤FDA warning cited significant current good manufacturing practice violations
- ➤Medline failed to thoroughly investigate unexplained batch discrepancies
- ➤Medline stock fell $2.56, or 7.16%, closing at $33.19
- ➤Reuters reported this was Medline's second FDA action in two months
- ➤FDA cited microbial contamination investigations and inadequate cleaning practices
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
Get started
Create a free account to read the full story.